Abstract: A coil spring (1) and support bearing (2) arrangement for suspension struts 3 with a shock absorber, supporting a steering knuckle of an automobile has a rolling-contact bearing (7), with an axis (x); a receiving body (6), arranged below the rolling-contact bearing (7) in which the rolling-contact bearing is inserted; and a coil spring (1). The coil spring (1) has a force application line (f), which is offset relative to the axis (x) of the rolling-contact bearing (7) at an angle (a). The coil spring (1) has a first portion (8), which, starting from the winding end (17), winds around the receiving body (6). The first portion (8) abuts the receiving body (6). The winding end (17) of the coil spring (1) is arranged in the area of the plane E1 formed by the force application line (f) and the axis (x).

Abstract: In the apparatus for removing solid medications from blister packs, comprising a shell-shaped bottom part and a hood-shaped top part, the bottom part (2) is provided with an axle (13). It further exhibits recesses (10), which are disposed concentrically to the axle (13). The one end of the axle (13) is configured as a rotational axis and translational guide for the top part (1). The top part (1) reaches over the bottom part (2) and exhibits a hub (15), which is supported on the axle (13) by means of a spring (6). Parallel to the hub (15) on the top part (1) there is disposed a ram (8), which, given an appropriate setting of the top part (1) relative to the bottom part (2), is aligned with respectively one of the recesses (10). The other end of the axle (13) is provided with a journal (11) for receiving a bearing plate (7) for the blister pack (5). The bearing plate (7) exhibits holes (9), which form with the recesses (10) of the bottom part (2) passages for the ram (8).

Abstract: The invention relates to a process for the preparation of an insulin derivative of the formula I ##STR1## in which R.sup.1 denotes H or H-Phe, R.sup.30 represents the radical of a naturally occurring L-aminoacid and R.sup.31 represents a physiologically acceptable organic group of neutral or basic character consisting of 1 to 3 .alpha.-aminoacids in which the terminal carboxyl function is present in the free form and which insulin derivative has an isoelectric point above 5.8, which comprises reacting an insulin of the formula I in which R.sup.30 denotes the radical of a genetically codable L-aminoacid and R.sup.31 represents OH or a protective group of the carboxyl function, with a peptide or aminoacid derivatives of the formula R-R.sup.30 -R.sup.31 consisting of 2 to 4 .alpha.-aminocacids, in which the terminal carboxyl function is in free form, in the presence of a trypsin-like endopeptidase at a pH value below the isoelectric point of the starting insulin.

Abstract: The invention relates to a process for the preparation of crystal suspensions of one or more insulin derivatives of the formula I ##STR1## R.sup.1 denotes H or H-Phe, R.sup.30 represents the radical of a neutral L-aminoacid which can be genetically coded andR.sup.31 represents a physiologically acceptable organic group of basic character with up to 50 carbon atoms, in the build-up of which 0 to 3 .alpha.-aminoacids participate and in which any terminal carboxyl function present can be free, as the ester function, as the amide function, as the lactone or reduced to CH.sub.2 OH, with an isoelectric point between 5.8 and 8.5,which comprises carrying out the crystallization in an aqueous medium close to the isoelectric point of the derivative or derivatives in the presence of an aromatic hydroxy compound, to crystals and crystal suspensions obtained by the process and to the use thereof.

Abstract: A medicament container, such as an injection ampule, for multiple administration of medicament suspensions the containers is filled with medicament so as to be free of gas bubbles, and includes at least one inert mixing element of suitable size whose density is different from that of the suspension. The mixing element acts to homogenize the medicament suspension as the container is shaken.

Abstract: A process for the preparation of insulin precursors of the formula (I) ##STR1## in which R is hydrogen or the presequence P.sub.m --Q.sub.n --, in which P is a sequence of naturally occurring amino acids with m being from 0 to 50, Q are basic natural amino acids, and n is an integer from 1 to 4, Y represents --Lys.sup.B29 --Z.sup.B30 --, in which Z denotes Ala, Thr or Ser, and the bridge extending from A-1 to A-21 is an insulin A-chain, the bridge extending from B-1 to B-30 represents an insulin B-chain, and X is a bridge which is bonded to the insulin A-chain at the amino group of A-1 and is bonded to the insulin B-chain at the .epsilon.-amino group of B-29-- in which case it is bonded to the free bond of Z.sup.

Abstract: The invention relates to insulin derivatives of the formula I ##STR1## in which R.sup.1 denotes H or H--Phe, R.sup.30 represents the radical of a neutral L-aminoacid and R.sup.31 represents a physiologically acceptable organic group of basic character with up to 50 carbon atoms, these derivatives having an isoelectric point between 5.8 and 8.5, processes for their preparation and their use, and agents containing these derivatives for the treatment of diabetes mellitus.

Abstract: The invention relates to a process for the preparation of insulin derivatives of the formula I ##STR1## in which R.sup.30 represents the radical of a neutral L-amino acid which can be genetically coded, X represents identical or different radicals of L-amino acids which can be genetically coded, at least one of which is a basic amino acid, it being possible for the C-terminal member to be homoserine-lactone, Y denotes Phe or H and n denotes 1, 2 or 3, by splitting of intermediates, proinsulin, preproinsulin or analogs thereof, which comprises carrying out the splitting reaction close to the isoelectric point of the insulin derivatives of the formula I in the presence of an aromatic hydroxy compound.

Abstract: The invention relates to a process for the preparation of insulins from analogs of preproinsulins, which comprises reacting preproinsulin analogs, at a pH below the isoelectric point of the insulins in the presence of trypsin or a trypsin-like endopeptidase, with an ester of natural amino acids or their derivatives and then cleaving off the ester group and other protective groups which may optionally be present.

Abstract: The invention relates to medicaments consisting of a physiologically acceptable excipient and an active compound combination of(a) an insulin derivative of the formula I ##STR1## in which R.sup.1 denotes H or H--Phe, R.sup.30 represents the radical of a neutral L-aminoacid and R.sup.31 represents a physiologically acceptable organic group of basic character with up to 50 carbon atoms, with an isoelectric point between 5.8 and 8.5, and(b) an insulin of the formula I in which R.sup.1 denotes H or H--Phe, R.sup.30 represents Ala, Thr or Ser and R.sup.31 denotes OH,and to its use for the treatment of diabetes mellitus.